Lucid Diagnostics shares are trading higher after the company announced data from its ESOGUARD BE-1 prospective, international, multicenter, single-arm study conducted to clinically validate performance of the EsoGuard Esophageal DNA test on samples collected with the EsoCheck Esophageal Cell Collection Device for detection of esophageal precancer and esophageal adenocarcinoma in a screening population.
$LUCD
Medical/Dental Instruments
Health Care
Lucid Diagnostics shares are trading higher after the company announced data from its ESOGUARD BE-1 prospective, international, multicenter, single-arm study conducted to clinically validate performance of the EsoGuard Esophageal DNA test on samples collected with the EsoCheck Esophageal Cell Collection Device for detection of esophageal precancer and esophageal adenocarcinoma in a screening population.